Cirrhosis: Difference between revisions
Jump to navigation
Jump to search
imported>David E. Volk m (subpages) |
imported>Robert Badgett (→Complications: Started Esophageal varices section) |
||
| Line 5: | Line 5: | ||
===Ascites=== | ===Ascites=== | ||
{{main|Ascites}} | {{main|Ascites}} | ||
==Esophageal varices== | |||
Patients with a platelet count of less than 40 and a palpable spleen are more likely to have esophageal varices.<ref name="pmid17914969">{{cite journal |author=Sharma SK, Aggarwal R |title=Prediction of large esophageal varices in patients with cirrhosis of the liver using clinical, laboratory and imaging parameters |journal=J. Gastroenterol. Hepatol. |volume=22 |issue=11 |pages=1909–15 |year=2007 |pmid=17914969 |doi=10.1111/j.1440-1746.2006.04501.x}}</ref> | |||
===Hepatic encephalopathy=== | ===Hepatic encephalopathy=== | ||
Revision as of 07:19, 25 January 2008
Cirrhosis is a "liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules."[1]
Complications
Ascites
Esophageal varices
Patients with a platelet count of less than 40 and a palpable spleen are more likely to have esophageal varices.[2]
Hepatic encephalopathy
Hepatorenal syndrome
Octreotide/Midodrine combined therapy can help according to a randomized controlled trial.[3]
Prognosis
MELD Score
The MELD Score can help predict mortality. An online calculator is available.
References
- ↑ Anonymous. Liver cirrhosis. National Library of Medicine. Retrieved on 2008-01-07.
- ↑ Sharma SK, Aggarwal R (2007). "Prediction of large esophageal varices in patients with cirrhosis of the liver using clinical, laboratory and imaging parameters". J. Gastroenterol. Hepatol. 22 (11): 1909–15. DOI:10.1111/j.1440-1746.2006.04501.x. PMID 17914969. Research Blogging.
- ↑ Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA (2007). "Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome". Dig. Dis. Sci. 52 (3): 742–8. DOI:10.1007/s10620-006-9312-0. PMID 17235705. Research Blogging.